GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and neck cancer ...

Second Quarter Net Sales and Adjusted EBITDA Above Guidance Driven by 51% OEM GrowthPreferred Stock Exchange and Public Offering Strengthen Financial PositionGuides to Third Quarter Net Sales of Approximately $15.9 Million Second Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period) Net sales were $16.2 million, compared to $13.2 million, up 23.0%.OEM net sales were $10.1 million, compared to $6.7 million, up 50.6%Gross Margin was 28.3%, compared to 24.0%, up 430 basis p ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and ...

Core Viewpoint - NANO Nuclear Energy Inc. is positioned to capitalize on the growing demand for clean and reliable nuclear energy solutions, driven by regulatory support and advancements in technology, particularly through its KRONOS MMR Energy System [2][11]. Financial Results - The company reported a cash and cash equivalents balance of $210.2 million as of June 30, 2025, a significant increase from $28.5 million on September 30, 2024, due to successful capital raises [9]. - Operating activities resulted in a cash outflow of $14.7 million for the nine months ended June 30, 2025, primarily due to increased operations and R&D expenses [3]. - Investing activities accounted for a cash outflow of $12.9 million, including $9.1 million for the acquisition of assets like the KRONOS MMR [4]. - Financing activities provided a net cash inflow of $209.3 million during the same period [5]. Technological Advancements & Regulatory Progress - The KRONOS MMR is advancing towards licensing and deployment in the U.S., with significant progress made in collaboration with the University of Illinois Urbana-Champaign [9][11]. - The company has received an approved Fuel Qualification Methodology Topical Report from the NRC and is focused on resuming licensing activities in Canada [9][11]. - NANO Nuclear aims to be the first commercial microreactor company in the U.S. to file for a construction permit application by late 2025 or early 2026 [11][12]. Operational Progress & Leadership - NANO Nuclear has made key appointments to its leadership team, including Rick Perry as Chairman of the Executive Advisory Board and Seth Berl as an independent director, enhancing its strategic capabilities [10][13]. - The company has initiated a recruitment drive to expand its engineering and project development teams, successfully hiring over a dozen engineers [13]. Strategic Collaborations & Market Position - NANO Nuclear signed a Memorandum of Understanding (MOU) with UrAmerica to secure resources and enhance its nuclear fuel supply chain [10]. - The company has been selected for inclusion in the Solactive Global Uranium & Nuclear Components Total Return Index, qualifying it for the Global X Uranium ETF, which enhances its market visibility [10][12]. - NANO Nuclear is exploring opportunities for vertical integration through collaborations and potential mergers and acquisitions to strengthen its competitive position [11][12].

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the second quarter ...

Core Viewpoint - Intchains Group Limited has reported a significant increase in its Ethereum (ETH) holdings and has adopted a long-term dollar-cost averaging strategy to enhance yield performance while navigating market volatility [1][5][9]. Financial Highlights - Revenue for Q2 2025 was RMB 43.2 million (US$ 6.0 million), a decrease of 64.9% from RMB 123.0 million in Q2 2024, primarily due to cyclical fluctuations and lower demand for mining machines [12][17]. - For H1 2025, revenue increased by 19.2% to RMB 175.6 million (US$ 24.5 million) compared to RMB 147.3 million in H1 2024, driven by strong sales of altcoin mining products [28]. - The company reported a net income of RMB 38.3 million (US$ 5.3 million) for Q2 2025, down 24% from RMB 50.4 million in Q2 2024 [24]. Operational Highlights - The company increased its ETH holdings to 8,816 ETH as of June 30, 2025, up 26% from March 31, 2025, and 55% from December 31, 2024 [1][9]. - The company has invested approximately RMB 41.6 million in R&D for new mining machines and upgrades since the beginning of 2025 [28]. - New product launches include the Aleo Mining Series and Goldshell Byte, which are designed to enhance competitiveness in the mining sector [28]. Strategic Focus - The company is committed to a long-term dollar-cost averaging strategy for ETH, which aims to build a digital asset reserve while mitigating short-term market volatility [5][8]. - Future strategies include expanding ETH reserves and launching yield-generating initiatives with FalconX to improve profitability [6][11]. - The company anticipates that these strategic moves will lead to tangible growth in 2026, capturing market share in the next altcoin cycle [7]. Cryptocurrency Management - The fair value of the company's cryptocurrency assets, excluding stablecoins, was RMB 157.7 million, primarily consisting of approximately 8,816 ETH valued at RMB 157.4 million (US$ 22.0 million) [12]. - The company plans to deploy a portion of its ETH holdings into yield-generating activities, including staking and liquidity provisioning [10]. Market Position - Intchains Group Limited has been identified as one of the top ETH treasury holders among public companies globally, reflecting its strategic focus on digital asset management [12][28].

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 vs. Second Quarter 2024 Financial Summary Total revenue for the quarter increased significantly to a record $1.4 million, compared to $0.3 million a year ago.Operating expenses were $5.9 million, compared to $3.6 million a ...

Core Insights - Fortress Biotech, Inc. achieved significant milestones in Q2 2025, including the acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharma, which provided approximately $28 million upfront and potential additional payments [2][3] - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date set for September 30, 2025 [2][6] - Journey Medical launched Emrosi™ for treating inflammatory lesions of rosacea, with commercial uptake expanding to cover 65% of U.S. commercial lives [2][5] Financial Performance - Fortress reported consolidated net revenue of $16.4 million for Q2 2025, an increase from $14.9 million in Q2 2024, primarily driven by dermatology product sales [11][18] - Consolidated cash and cash equivalents rose to $74.4 million as of June 30, 2025, up from $57.3 million at the end of 2024 [11][16] - The company recorded a net income attributable to common stockholders of $13.4 million, or $0.50 per share basic, compared to a net loss of $(13.3) million in the same quarter of the previous year [11][18] Regulatory Developments - The FDA granted Orphan Drug Designation to Mustang Bio for MB-101, enhancing the potential of the combination strategy with MB-108 for treating high-grade gliomas [6][12] - The NDA submission for CUTX-101 is under priority review, with expectations for a Priority Review Voucher upon approval [2][6] Commercial Updates - Journey Medical's Emrosi™ has seen expanded payer access, now covering over 100 million commercial lives in the U.S., up from 54 million in May 2025 [10][12] - The commercial launch of Emrosi™ began on April 7, 2025, following initial distribution and prescription filling [10][12] Corporate Developments - Fortress Biotech's subsidiary Journey Medical was added to the small-cap Russell 2000 Index and the broad-market Russell 3000 Index as of June 27, 2025 [8]

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Expo ...

Trust Stamp announced that it filed its 2025 Q2 10-Q after the Nasdaq market closed on August 14th, 2025, together with announcing strong growth in customer enrollment and user completions on its SaaS Orchestration LayerAtlanta, GA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI) announced that: It filed its Q2 10-Q report for the six months ended 30 June 2025 after the Nasdaq market closed on August 14th, 2025. Net recognised revenue for the three months ended 30 June 2025 was $0.81 million, ...